Francis Collins via Getty Images
NIH corrals biopharma companies, regulators and trial networks to coordinate Covid-19 R&D
Francis Collins’ grand plan to bring order to the chaotic rush for Covid-19 vaccines and treatments is here.
The public-private partnership that the NIH director teased a few days ago will be known as ACTIV or Accelerating COVID-19 Therapeutic Interventions and Vaccines. By compiling resources, leveraging existing networks, lobbying regulators and setting up a steering committee to prioritize promising candidates, the goal is to generate more comprehensive data quicker.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters